Lakshminarayana Vogeti

发表

Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.

L. Stewart, R. V. van Etten, T. Haack, 2011, Cancer cell.

Cephalosporin-derived inhibitors of β-Lactamase. Part 4: The C3 substituent

J. Buynak, V. Doppalapudi, L. Vogeti, 2002 .

Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages

Michael D. Kaufman, L. Davis, R. Ruiz-Soto, 2021, Molecular Cancer Therapeutics.

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.

Stacie L. Bulfer, O. Rosen, M. Heinrich, 2019, Cancer cell.

Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2

L. Stewart, Michael D. Kaufman, D. Flynn, 2015, Molecular Cancer Therapeutics.

Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.

P. Hipskind, D. Clawson, D. Manglicmot, 2015, Journal of medicinal chemistry.

Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region.

Michael D. Kaufman, Hidong Kim, M. Feese, 2010, Bioorganic & medicinal chemistry letters.

Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues.

R. Himes, D. Powell, K. Roby, 2007, Bioorganic & medicinal chemistry.

Discovery of Acyl Ureas as Highly Selective Small Molecule CSF1R Kinase Inhibitors.

Stacie L. Bulfer, Michael D. Kaufman, B. Le Bourdonnec, 2022, Bioorganic & medicinal chemistry letters.

Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT).

Stacie L. Bulfer, Michael D. Kaufman, B. Le Bourdonnec, 2022, Bioorganic & medicinal chemistry letters.

Scaffold hopping via ring opening enables identification of acyclic compounds as new complement Factor D inhibitors.

K. Polach, Y. Babu, P. Kotian, 2022, Bioorganic & medicinal chemistry.